In this interview, Hermann Einsele discusses the future perspectives of anti-CD38 antibodies, highlighting their role in first-line treatment for both transplant-eligible and -ineligible patients as well as applications in the second line and smoldering MM. Einsele also discusses outcomes from key trials and outlines potential combinations of anti-CD38s with emerging therapies, including cereblon E3 ligase modulators (CELMoDs), bispecific antibodies, and chimeric antigen receptor (CAR) T-cell therapies.
This educational resource is independently supported by Sanofi. All content was developed by SES in collaboration with an expert steering committee. Funders were allowed no influence on the content of this resource.
Hosted on Acast. See acast.com/privacy for more information.
Multiple Myeloma Hub